Time: 8AM PST / 11AM EST / 5PM CET
Date: August 3, 2023
Aro Biotx is focused on developing Centyrin-siRNA conjugates for treatment of extrahepatic genetic diseases. Our lead program employs a CD71 Centyrin for targeting to muscle together with an siRNA for glycogen synthase 1 for the treatment of Pompe disease. Aro is also building a portfolio of Centyrin molecules for delivery to various cell types together with siRNAs for intracellular targets involved in disease pathologies. The presentation will provide a brief introduction to Aro’s platform technology together with a program summary for our lead molecule for Pompe disease. The history of the discovery of both Centyrin and siRNA will be included, together with recent data supporting progression of the program into the clinic later this year.
